NCT04941053

Brief Summary

Coronavirus disease pandemic has been started in late 2019. Since this date, the number of cases has been increased reaching 32.7 million cases worldwide in 27 September, 2020. . Herd immunity is achieved when enough people become immune to a virus to stop its spread. Around 70% to 90% of a population needs to be immune to protect the uninfected. In A Spanish study of more than 30,000 people estimates that around just 5% of the Spanish population has developed antibodies

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 3, 2021

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

June 23, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 28, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

October 25, 2022

Status Verified

October 1, 2022

Enrollment Period

3 months

First QC Date

June 23, 2021

Last Update Submit

October 24, 2022

Conditions

Covid19

Outcome Measures

Primary Outcomes (1)

  • seroprevalnce

    antibody measurement

    3-6-2021 to 30-8-2021

Study Arms (2)

group 1 chronic haemodialysis patients

seroprevalnce of COVID 19

Diagnostic Test: laboratory test

healthy control

seroprevalnce of COVID 19

Diagnostic Test: laboratory test

Interventions

laboratory testDIAGNOSTIC_TEST

seroprevalnce

group 1 chronic haemodialysis patientshealthy control

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

group 1 patients coming to hemodialysis unit group 2 relative to patients coming to hemodialysis unit, medical staff

You may qualify if:

  • patient accept to participate

You may not qualify if:

  • vaccinated people

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University

Sohag, 82733, Egypt

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum sample

MeSH Terms

Conditions

COVID-19

Interventions

Clinical Laboratory Techniques

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • N S shafik, lecturer

    Sohag University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

June 23, 2021

First Posted

June 28, 2021

Study Start

June 3, 2021

Primary Completion

August 30, 2021

Study Completion

December 30, 2021

Last Updated

October 25, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

to protect privacy of data of patients

Locations

EG(1)